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Introduction. Patients treated with vitamin K antagonists (VKA) are at increased risk of intracranial haemorrhage (ICH). The
purpose of our study was to determine the quality of previous anticoagulation control in patients with VKA-associated ICH.
Materials and Methods. We prospectively assessed every consecutive patient admitted to our stroke unit with VKA-associated
ICH between 2013 and 2016. Demographic, clinical, and radiological variables, as well as consecutive international normalized
ratios (INR) during 7 previousmonths, were extracted. Time in therapeutic range (TTR), time over range (TOR), time below range
(TBR), and percentage of INR within range (PINRR) were calculated. Results and Discussion. The study population comprised 53
patients. Mean age was 79 years; 42% were women. Forty-eight patients had atrial fibrillation (AF) and 5 mechanical prosthetic
valves. Therapeutic or infratherapeutic INR on arrival was detected in 64.4% of patients (95% CI 2.7 to 3.2). TTR was 67.8% (95%
CI: 60.2 to 75.6 %) and PINRR was 75% (95% CI: 49.9-100). TOR was 17.2% (95% CI: 10.4 to 23.9% ) and TBR was 17% (95% CI:
10.6 to 23.9%). Conclusion. VKA-associated ICH happens usually in the context of good chronic anticoagulation control. Newer
risk assessment methods are required.
1. Introduction
Oral anticoagulant (OAC)medication is the mainstay of pro-
phylaxis for embolism. It reduces the risk of cardioembolic
stroke by 66% in patients with atrial fibrillation (AF) [1] and
by 75% in those with mechanical heart valve prostheses [2].
However, it increases the risk of intracranial haemorrhage
(ICH), which is the most feared and lethal complication of
this therapy [3, 4].
Treatment with OACs accounts for approximately 20% of
all cases of ICH,most of which are associatedwith the vitamin
K antagonists (VKAs), acenocoumarol and warfarin [5]. ICH
affects 0.3-1.5% of patients taking VKAs [5, 6] and is more
severe than non–VKA-associated ICH [5]
Advancing age and newer AF detection methods [7,
8] have led to an increase in the prevalence of AF [9–11]
and OAC use. Findings on anticoagulant medication and
risk of complications in patients taking VKAs are mixed.
While most publications found that a lower time in the
therapeutic range (TTR) was associated with an elevated risk
of both haemorrhage and ischemia [12–16], few studies have
specifically addressed ICH. Moreover, most studies did not
carefully examine other major anticoagulation parameters
such as the time over range (TOR), time below range (TBR),
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and percentage of international normalized ratios (INR) in
the therapeutic range (PINRR).
Assessment of anticoagulation on admission using the
INR has been amatter of debate. INR on admission is usually
within range and does not correlate with prognosis or with
ICH volume [17]. Hence, reversal of anticoagulation with
vitaminK, fresh frozenplasma, or prothrombin complex does
not appear to affect outcomes although evidence comes from
observational studies and not from randomized controlled
trials [18, 19].
In addition, publications on the precise clinical charac-
teristics of OAC-induced ICH and its relationship with long-
term management of OAC are scarce [20]. With the arrival
of safer direct oral anticoagulants (DOAC) and restrictive
government regulations on switching from VKAs in some
countries, which are based mainly on long-term control of
OAC medication, the association between ICH and VKAs
seems more crucial than ever.
Our objective was to determine the quality and charac-
teristics of OAC managed with VKAs in patients admitted
to our institution with ICH. Secondary endpoints included
prognosis of VKA-ICH and treatment used to prevent sys-
temic embolism after ICH.
2. Materials and Methods
We conducted a prospective, single-centre observational
study of every consecutive patient admitted to the Stroke Unit
of Ramon yCajal UniversityHospital,Madrid, Spain, because
of VKA-related intraparenchymal ICH between July 2013
and December 2016. We included patients anticoagulated
owing toAFormechanical heart valves.We excluded patients
with subdural haematomas, subarachnoid haemorrhages,
and haemorrhagic transformation of ischaemic stroke. Our
hospital is a comprehensive stroke centre having a catchment
population of 1,000,000 people that forms part of the Madrid
Stroke Network (MSS). MSS is composed of nine hospitals
provided with stroke units and 17 community hospitals work-
ing within a coordinated system to guarantee specialized
care for all stroke patients in the region of Madrid, with a
population of around 6.3 million inhabitants.
On admission, we assessed previous vascular risk factors,
conditions requiring treatment with anticoagulant medica-
tion, and previous thromboembolic and haemorrhagic risk
scores (CHA
2
DS
2
-VASc and HASBLED) [21, 22]. We also
examined additional previous treatment with antiplatelet
agents and presence or absence of leukoaraiosis on cranial
computed tomography (CT) scans on admission.
We prospectively recorded vital signs, National Institute
of Health Stroke Scale (NIHSS) score on admission, seizures,
and the modified Rankin scale (mRS) score before the stroke
and 3months after the stroke.We also recorded clinical wors-
ening during admission, repetition of CT scans, haematoma
expansion, performance of magnetic resonance imaging
(MRI), length of stay, location of the haemorrhage, ICH vol-
ume calculated using the ABC/2 formula [23], and the
presence/absence of underlying structural lesions or intra-
ventricular clot. We gathered data on treatment of ICH
(medical with reversal agents and/or surgery). Anticoagulant
Table 1: Baseline characteristics.
BASELINE CHARACTERISTICS (N=53)
Age, median (range) years 79 (56-93)
Sex (female) 26 (42%)
Previous mRSN (%)
(i) 0-3 41 (91%)
(ii) 4-5 4 (9%)
Arterial hypertension N (%) 4 (9%)
Diabetes mellitus N (%) 13 (25%)
Dyslipidemia N (%) 23 (43%)
Previous stroke:
(i) TIA N (%) 7 (13.21%)
(ii) Ischaemic N (%) 2 (5%)
(iii) Haemorrhagic N (%) 3 (6.5%)
(iv) Both N (%) 2 (5%)
HASBLED median (p25-p75) 2.5 (2-3)
CHAD
2
S
2
-VASc median (p25-p75) 4 (3-5)
Condition requiring anticoagulation:
(i) Atrial fibrillation N (%) 48 (90.6%)
(ii) Mechanical heart valves N (%) 5 (9.4%)
Concomitant medications:
(i) Antiplatelet agents N (%) 3 (6.5%)
(ii) Statins N (%) 19 (43.2%)
Leukoaraiosis N (%) 24 (47%)
TIA: transient ischaemic attack. VKA: vitamin K antagonist.
treatment at discharge and 3 months after ICH were also
reviewed.
We collected the INR during the previous 7 months and
calculated the TTR, TOR, TBR, and PINRR based on the
Rosendaal method [24]. We excluded patients where INR
data were incomplete or not available. We also evaluated INR
on admission and other coagulation parameters.Therapeutic
ranges were considered to be between 2 and 3 for AF and
between 2.5 and 3.5 for mechanical prosthetic valves.
Data were analysed using Microsoft Excel 2013 and Stata
SE 12.0.
3. Results
3.1. Study Population (Table 1). We included a total of 53 con-
secutive patients receiving VKAs. Forty-eight were anticoag-
ulated owing to AF, and 5 had mechanical prosthetic heart
valves. Mean age on admission was 79 years (interquartile
range [IQR] 76-84), and 26 (48%) patients were women. 91%
were independent (mRS 0-3) before ICH. Seven patients had
had a previous stroke, which had been haemorrhagic in 4
cases. The median CHA
2
DS
2
-VASc score was 4 (IQR, 3-5).
The median HASBLED was 2.5 (IQR, 2-3). Three patients
were taking antiplatelet agents and 19 statins.
3.2. Characteristics of ICH (Tables 2 and 3)
3.2.1. Clinical. Themedian NIHSS on admission was 13 (IQR,
4-20). After 3 months, only 13 patients (24%) remained
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Table 2: Characteristics of ICH.
CLINICAL AND RADIOLOGICAL CHARACTERISTICS OF
ICH
Length of stay, (days, range) 7 (1-38)
SBP on admission (mmHg, range) 160 (110-242)
DBP on admission (mmHg, range) 81.5 (40-146)
HR on admission (bpm, range) 79 (41-150)
Glycemia on admission (mg/dl, range) 137 (76-280)
ICH volume (cm) 23.7 (mean=15)
Baseline NIHSS 13 (0-42)
NIHSS at discharge 16 (0-42)
NIHSS at discharge (survivors) 2 (0-16)
Structural lesion
(i) None 51 (96%)
(ii) Cavernoma N (%) 2 (4%)
In-hospital mortality N (%) 27 (51%)
3-month mortality N (%) 29 (64.4%)
Intraventricular extension N (%) 20 (38.4%)
Seizures N (%) 2 (4%)
Clinical worsening N (%) 27 (61.4%)
Repetition of imaging studies N (%) 22 (50%)
Haematoma expansion N (%) 13 (59%)
Withdrawal of care N (%) 11 (25%)
mRS after 3 months N (%)
(i) 0-3 13 (29%)
(ii) 4-6 40 (71%)
Haemorrhage locationN (%)
(i) Deep 20 (38%)
(ii) Lobar 15 (29%)
(iii) Intraparenchymal extensive 9 (17%)
(iv) Intraventricular 1 (2%)
(v) Brainstem 6 (11.5%)
(vi) Cerebellum 2 (4%)
ICH: intracranial haemorrhage. SBP: systolic blood pressure. DBP: diastolic
blood pressure. HR: heart rate. NIHSS: National Institutes of Health Stroke
Scale. mRS: Modified Rankin Scale. Values are shown as median (range)
unless otherwise specified.
independent (mRS 0-3) and 34 (64%) had died. The mean
length of hospital stay was 7 days. Clinical worsening during
hospitalization was recorded in 33 patients (61%). Imag-
ing was repeated in 26 (50%) and disclosed haematoma
expansion in 59% of those who underwent further CT or
MRI.
3.2.2. Radiological. Mean ICH volume was 24 cm3. Only 2
patients had underlying structural lesions (cavernomas). The
location was heterogeneous: basal ganglia, 38 %; lobar, 29%;
intraparenchymal extensive, 17%; primary intraventricular,
2%; posterior fossa, 15%. Intraventricular extension was
present in 38.4%.
Table 3: Treatment.
TREATMENT
Haemorrhage treatmentN (%)
(i) None 16 (30.8%)
(ii) Vitamin K 6 (11.5%)
(iii) Prothrombin 0 (0%)
(iv) Prothrombin and vitamin K 26 (50%)
(v) Surgical 4 (7.7%)
Treatment at dischargeN (%)
(i) None 10 (41.6%)
(ii) Antiplatelet agents 3 (12.5%)
(iii) VKAs 2 (8.3%)
(iv) VKAs and antiplatelet agents 0 (0%)
(v) Dabigatran 2 (8.3%)
(vi) Rivaroxaban 0 (0%)
(vii) Apixaban 0 (0%)
(viii) NOAC and aspirin 0 (0%)
(ix) LAA closure 5 (20.8)
(x) Prophylactic heparin
Treatment at 3 months N (%)
(i) None 0 (0%)
(ii) Antiplatelet agents 2 (9.1%)
(iii) VKAs 2 (9.1%)
(iv) VKAs and antiplatelet agents 0 (0%)
(v) Dabigatran 4 (18.2%)
(vi) Rivaroxaban 7 (31.8 %)
(vii) Apixaban 2 (9.1%)
(viii) NOAC and aspirin 0 (0%)
(ix) LAA closure 3 (13.6%)
(x) Prophylactic heparin 1 (4.5%)
Treatment changed 3 months after discharge. 15/22
VKA:VitaminK antagonist. NOAC: novel oral anticoagulant. LAA: left atrial
appendage.
3.2.3. Treatment. Care was withdrawn on admission in 11 pa-
tients, all of whom died. Further 5 patients did not receive
reversal of anticoagulation or surgery. 26 patients were treat-
ed with vitamin K and prothrombin and 6 patients were
treated with vitamin K alone. Four patients were treated sur-
gically (2with decompressive craniectomy and 2with ventric-
ular drain placement) and we do not have data about anti-
coagulation reversal therapy. In one patient data were not
available.
Upon discharge, 3 patients (12.5%) received antiplatelet
medication, 2 (8.3%) VKAs, 2 (8.3%) DOAC, and 5 (20.8%)
prophylactic low-molecular-weight heparin. Ten patients
(41.6%) did not receive any antithrombotic treatment imme-
diately after discharge.
After 3 months, only 2 of the surviving patients (9.1%)
continued to receive antiplatelet agents, further 2 (9.1%)
received acenocoumarol because both had amechanical heart
valve, 13 (59.1%) received DOAC, and 3 (13.6%) underwent
left atrial appendage closure. Overall, in 15 out of 22 patients,
treatment was changed 3 months after discharge, and there
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were no patients without treatment at this point. Neither
thrombotic nor haemorrhagic events were detected during
follow-up.
3.2.4. Prognostic Factors (Table 4). The only statistically sig-
nificant differences between patients who died and survivors
were found for ICH volume (33.9 versus 12.5 cm3, p<0.0002),
INR on admission (3.3 versus 2.5, p<0.01), and NIHSS score
on admission (25 versus 6, p<0.0001).
3.3. Anticoagulation
3.3.1. INR on Admission. Median INR on admission was 2.71
(IQR, 2.4-3.5) for patients with AF and 4.01 (IQR, 3.7-4.6)
in patients with mechanical heart valves. On admission, 29
(54.7%) patients were within therapeutic range and 20 (37.7
%) had supratherapeutic INR and 4 (7.5 %) had infrathera-
peutic INR. We did not find a statistically significant correla-
tion between INR on admission and location of the ICH.
3.3.2. Long-Term Anticoagulation. Mean TTR during the
previous 7 months calculated using the Rosendaal method
was 67% (95% CI: 60.2 to 75.6 %), and the PINRR was 75%
(95% CI: 49.9-100). TOR was 17.2 % (95% CI: 10.4 to 23.9% )
and TBR was 17% (95% CI: 10.6 to 23.9%).
4. Discussion
Our series confirms the gloomy prognosis of VKA-ICH [9,
25, 26], withmortality rates over 50% after 3months and high
rates of disability. These results are especially striking when
previous mRS are taken into account, with almost 9 out of
every 10 patients being independent before ICH.
Mortality was significantly associated (p<0.05) with only
3 variables: higher INR on admission, higher NIHSS scores,
and larger ICH volumes on admission. The INR level on
admission has not been consistently associated with prog-
nosis of ICH [19, 27] probably because of longer times from
onset of symptoms to CT during previous years, when stroke
symptoms were underrecognized by the general population.
As in previous series, location of the ICH was also
heterogeneous and similar to non–VKA-related ICH [25].
The latter finding contrasts with the generally held belief that
lobar ICH is more common in patients treated with OAC
than hypertensive haemorrhages. No differences in location
were observed when patients were stratified according to INR
levels on admission.
We also found that even though INR is a prognostic fac-
tor, most patients do not present with supratherapeutic INR
on admission [10, 28]. In fact, in our sample, supratherapeutic
INR were seen in 37.7 % of patients, whereas 7.5% presented
with infratherapeutic levels of anticoagulation. These data
should be taken with caution due to the small numbers but
could imply an INR-dependent risk of haemorrhage that is
increased, even when therapeutic levels have been achieved,
possibly owing to various etiologies that predispose to ICH.
The increased likelihood of ICH was not due to the fact
that patients were undergoing adjustment of OAC, as every
patient had been on treatment for at least 7 months.
Table 4: Differences between patients who died and survivors.
Patients who
died (N=29)
Survivors
(N=22)
Agemean (years) 78 80 n.s.
SBPmean (mmHg) 170 156 n.s.
DBPmean (mmHg) 89 81 n.s.
HRmean (bpm) 83 79 n.s.
Glycemiamean (mg/dl) 160 132 n.s.
HASBLEDmedian 2.8 2.4 n.s.
CHAD2S2-VAScmedian 3.5 4.23 n.s.
NIHSSmedian 25 6.1 p<0.05
Leukoaraiosis% 39% 47% n.s.
Intraventricular extension% 56% 33% n.s.
Haemorrhage locationN (%)
(i) Deep 18.5% 41.6% n.s.
(ii) Lobar 29.6% 45.8% n.s.
(iii) Intraparenchymal extensive 14.8% 8.3% n.s.
(iv) Intraventricular 33.3% 0 n.s.
(v) Brainstem 0 % 8.3% n.s.
(vi) Cerebellum 3.7% 0 % n.s.
ICH volume (cm3) 33.9 12.5 p<0.05
INR on admission (mean) 3.3 2.5 p<0.05
n.s.: not statistically significant differences. SBP: systolic blood pressure.
DBP: diastolic blood pressure. HR: heart rate. VKA: vitamin K antagonist.
NIHSS: National Institutes of Health Stroke Scale.
We did not find a relationship between TOR and TBR in
ICH, as suggested by previous studies [12], since TOR and
TBR were very similar in the present study.
We examined trends in resumption of anticoagulation
treatment after ICH and found that only 10% of surviv-
ing patients did not receive anticoagulant treatment after
discharge. Of the remaining patients, none of those who
underwent left atrial appendage (LAA) closure or those
who were anticoagulated experienced thrombotic or haem-
orrhagic events during follow-up. This finding differs from
those of Poli et al. [29] and might be related to the small size
of our sample, short follow-up, and use of DOAC instead
of VKAs in our series. As LAA closure was still being
implemented while data were being collected, it is highly
likely that more patients will undergo this procedure in the
future. However, DOAC and LAA closure [30, 31] have both
proven to be at least as effective asVKAs for preventing stroke
without increasing the risk of haemorrhage.
In many developed countries, the arrival of DOAC has
triggered strict administrative regulations regarding switch-
ing from VKAs, which requires deficient TTR during the
previous months. Nevertheless, we found that anticoagula-
tion was generally well controlled in patients with ICH: the
mean TRT was 67%, which is above Spanish government
requirements for switching treatment (65%) [32].
Our study has several limitations. First, it is a single-
centre study that might be influenced by the characteris-
tics of the study population, by local general practitioners’
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expertise in controlling anticoagulation, and by our own
clinical practice. However, a good global TTR has previously
been reported in our country [33]. Another drawback is
that although patients were included prospectively, we retro-
spectively collected their previous INR. In addition, we also
lacked a control group, which would have allowed us a direct
comparison of anticoagulation control in patients with and
without ICH.
5. Conclusion
In summary, we found that VKA-related ICH is a devastating
disorder that tends to affect patients with well-managed long-
term anticoagulation medication, as measured by TTR and
other indexes. VKA-related ICH can be partially avoidedwith
easier and earlier access to newer and safer treatments such as
DOAs.
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